DNA vaccines against cytomegalovirus: Current progress

International Journal of Antimicrobial Agents

Volumn 19, Issue 3, 2002, Pages 169-172

  Temperton, N J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Antibody; CTL; Cytomegalovirus; DNA vaccines; Protection

Indexed keywords

ALUMINUM PHOSPHATE; CYTOMEGALOVIRUS VACCINE; DNA VACCINE; PLASMID DNA; SYNAPTOTAGMIN;

ANIMAL MODEL; ANTIBODY RESPONSE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GENE CONSTRUCT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; VACCINATION;

EID: 0036128804     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(01)00492-7     Document Type: Review

References (37)

1. Cytomegalovirus
2. A prospective study of primary cytomegalovirus infection during pregnancy: final report
3. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome
4. Encouraging prospects for immunisation against primary cytomegalovirus infection
5. A review of genetic differences between limited and extensively passaged human cytomegalovirus strains
6. Vaccination against cytomegalovirus, the changeling demon
7. Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus
8. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response
9. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes
10. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T- cell receptor usage of pp65-specific CTL
11. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression
12. Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB
13. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects
14. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant
15. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection
16. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response
17. Coexpression of truncated human cytomegalovirus gH with the UL115 gene product or the truncated human fibroblast growth factor receptor results in transport of gH to the cell surface
18. Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73)
19. The product of human cytomegalovirus UL73 is a new polymorphic structural glycoprotein (gpUL73)
20. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs
21. DNA vaccines for viral infections: basic studies and applications
22. DNA vaccines for viral diseases
23. Direct DNA immunization of mice with plasmid DNA encoding the tegument protein pp65 (ppUL83) of human cytomegalovirus induces high levels of circulating antibody to the encoded protein
24. DNA immunization confers protection against murine cytomegalovirus infection
25. Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65)
26. Enrichment of immediate-early 1 (m123/pp89) peptide-specific CD8 T cells in a pulmonary CD62L(lo) memory-effector cell pool during latent murine cytomegalovirus infection of the lungs
27. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization
28. Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83
29. DNA vaccines: immunology, application, and optimization
30. Enhancement of DNA vaccine potency using conventional aluminum adjuvants
31. Induction of neutralizing antibody against human cytomegalovirus (HCMV) with DNA-mediated immunization of HCMV glycoprotein B in mice
32. The prime-boost strategy: exciting prospects for improved vaccination
33. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies
34. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting
35. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne)
36. Optimization of DNA immunization against human cytomegalovirus